Symbols / CTXR
CTXR Chart
About
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 16.78M |
| Enterprise Value | 24.39M | Income | -35.89M | Sales | 3.94M |
| Book/sh | 3.57 | Cash/sh | 0.34 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | 0.27 | PEG | — |
| P/S | 4.25 | P/B | 0.21 | P/C | — |
| EV/EBITDA | -0.67 | EV/Sales | 6.18 | Quick Ratio | 0.31 |
| Current Ratio | 0.99 | Debt/Eq | 1.96 | LT Debt/Eq | — |
| EPS (ttm) | -2.46 | EPS next Y | 2.79 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-13 | ROA | -17.68% |
| ROE | -47.85% | ROIC | — | Gross Margin | 79.99% |
| Oper. Margin | -214.14% | Profit Margin | 0.00% | Shs Outstand | 22.38M |
| Shs Float | 21.88M | Short Float | 12.58% | Short Ratio | 9.09 |
| Short Interest | — | 52W High | 2.48 | 52W Low | 0.63 |
| Beta | 1.52 | Avg Volume | 852.40K | Volume | 415.69K |
| Target Price | $6.00 | Recom | Buy | Prev Close | $0.67 |
| Price | $0.75 | Change | 12.65% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$0.75
Latest analyst target
3. DCF / Fair value
$-32.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.75
Low
$6.00
High
$6.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-04 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-08-13 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-06-30 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-06-10 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-06-09 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-05-23 | down | Maxim Group | Buy → Hold | — |
| 2025-05-15 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-18 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-01-07 | main | D. Boral Capital | Buy → Buy | $9 |
| 2024-12-30 | up | D. Boral Capital | Hold → Buy | $9 |
| 2024-11-22 | down | D. Boral Capital | Buy → Hold | — |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-11-11 | main | D. Boral Capital | Buy → Buy | $6 |
| 2024-08-19 | main | EF Hutton | Buy → Buy | $6 |
| 2024-08-08 | main | EF Hutton | Buy → Buy | $6 |
| 2024-08-05 | main | EF Hutton | Buy → Buy | $6 |
| 2024-07-15 | init | EF Hutton | — → Buy | $6 |
| 2024-05-31 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-02-14 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-08-10 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
- New Jersey tax program turns Citius Pharma losses into $3.8M cash - Stock Titan ue, 24 Feb 2026 13
- Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - PR Newswire ue, 23 Dec 2025 08
- Analysts Expect Breakeven For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Before Long - simplywall.st hu, 12 Feb 2026 08
- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Is Expected To Breakeven In The Near Future - Yahoo Finance Wed, 12 Nov 2025 08
- CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Wed, 24 Dec 2025 08
- Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIRâ„¢ - PR Newswire Fri, 13 Feb 2026 08
- Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView Fri, 13 Feb 2026 13
- Citius Pharmaceuticals Posts First Revenue Amid Listing Risk - TipRanks Fri, 13 Feb 2026 08
- Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga Wed, 24 Dec 2025 08
- Citius Oncology stock soars on expanded AI collaboration for LYMPHIR launch - Investing.com Fri, 21 Nov 2025 08
- Citius Pharma (NASDAQ: CTXR) closes $6.0M registered direct, issuing 3,973,510 shares - Stock Titan ue, 21 Oct 2025 07
- Citius Pharmaceuticals (CTXR) Reports Earnings Miss with Increas - GuruFocus ue, 23 Dec 2025 08
- Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire ue, 12 Aug 2025 07
- Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know - Benzinga Fri, 13 Feb 2026 14
- Citius Oncology stock tumbles after $18M capital raise - Investing.com ue, 09 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2415 | 36 | — | Conversion of Exercise of derivative security at price 0.02 per share. | HOLUKA EUGENE MYRON | Director | — | 2024-03-13 00:00:00 | D |
| 1 | 12071 | 181 | — | Conversion of Exercise of derivative security at price 0.02 per share. | WEBB CAROL A | Director | — | 2024-03-04 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -38.20M | -41.79M | -36.54M | -33.14M |
| TotalUnusualItems | 0.00 | 166.56K | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 166.56K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -37.43M | -39.14M | -32.54M | -33.64M |
| ReconciledDepreciation | 214.25K | 209.61K | 194.32K | 179.68K |
| EBITDA | -38.20M | -41.79M | -36.54M | -33.14M |
| EBIT | -38.42M | -42.00M | -36.73M | -33.32M |
| NetInterestIncome | -157.70K | 758.00K | 1.18M | 251.40K |
| InterestExpense | 267.78K | 0.00 | 10.84K | |
| InterestIncome | 110.08K | 758.00K | 1.18M | 251.40K |
| NormalizedIncome | -37.43M | -39.14M | -32.54M | -33.64M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -37.43M | -39.14M | -32.54M | -33.64M |
| TotalExpenses | 38.53M | 42.00M | 36.73M | 33.32M |
| TotalOperatingIncomeAsReported | -38.53M | -42.00M | -36.73M | -33.32M |
| DilutedAverageShares | 11.07M | 6.73M | 6.05M | 5.84M |
| BasicAverageShares | 11.07M | 6.73M | 6.05M | 5.84M |
| DilutedEPS | -3.38 | -5.97 | -5.57 | -5.75 |
| BasicEPS | -3.38 | -5.97 | -5.57 | -5.75 |
| DilutedNIAvailtoComStockholders | -37.43M | -40.19M | -33.69M | -33.64M |
| NetIncomeCommonStockholders | -37.43M | -40.19M | -33.69M | -33.64M |
| OtherunderPreferredStockDividend | 0.00 | 1.05M | 1.15M | 0.00 |
| NetIncome | -37.43M | -39.14M | -32.54M | -33.64M |
| MinorityInterests | 2.31M | 287.00K | 0.00 | |
| NetIncomeIncludingNoncontrollingInterests | -39.74M | -39.43M | -32.54M | -33.64M |
| NetIncomeContinuousOperations | -39.74M | -39.43M | -32.54M | -33.64M |
| TaxProvision | 1.06M | 576.00K | 576.00K | 576.00K |
| PretaxIncome | -38.68M | -38.85M | -31.97M | -33.06M |
| OtherIncomeExpense | 2.39M | 3.59M | 226.47K | |
| OtherNonOperatingIncomeExpenses | 2.39M | 3.59M | 59.92K | |
| SpecialIncomeCharges | 0.00 | 166.56K | ||
| OtherSpecialCharges | -166.56K | |||
| NetNonOperatingInterestIncomeExpense | -157.70K | 758.00K | 1.18M | 251.40K |
| InterestExpenseNonOperating | 267.78K | 0.00 | 10.84K | |
| InterestIncomeNonOperating | 110.08K | 758.00K | 1.18M | 251.40K |
| OperatingIncome | -38.53M | -42.00M | -36.73M | -33.32M |
| OperatingExpense | 38.53M | 42.00M | 36.73M | 33.32M |
| ResearchAndDevelopment | 9.16M | 11.91M | 14.82M | 17.66M |
| SellingGeneralAndAdministration | 29.37M | 30.09M | 21.91M | 15.66M |
| GeneralAndAdministrativeExpense | 29.37M | 30.09M | 21.91M | 15.66M |
| OtherGandA | 18.53M | 18.25M | 15.30M | 11.75M |
| SalariesAndWages | 10.84M | 11.84M | 6.62M | 3.91M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 18.07M | 7.25M | 6.35M | 5.85M |
| ShareIssued | 18.07M | 7.25M | 6.35M | 5.85M |
| TotalDebt | 1.81M | 262.87K | 481.25K | 678.23K |
| TangibleBookValue | -34.60M | -32.07M | 22.08M | 34.08M |
| InvestedCapital | 68.55M | 70.08M | 90.83M | 102.83M |
| WorkingCapital | -16.98M | -21.59M | 28.59M | 40.03M |
| NetTangibleAssets | -34.60M | -32.07M | 22.08M | 34.08M |
| CapitalLeaseObligations | 813.27K | 262.87K | 481.25K | 678.23K |
| CommonStockEquity | 67.55M | 70.08M | 90.83M | 102.83M |
| TotalCapitalization | 67.55M | 70.08M | 90.83M | 102.83M |
| TotalEquityGrossMinorityInterest | 77.53M | 74.10M | 91.43M | 103.43M |
| MinorityInterest | 9.98M | 4.02M | 600.38K | 600.38K |
| StockholdersEquity | 67.55M | 70.08M | 90.83M | 102.83M |
| RetainedEarnings | -238.80M | -201.37M | -162.23M | -129.69M |
| AdditionalPaidInCapital | 306.34M | 271.44M | 253.06M | 232.37M |
| CapitalStock | 18.07K | 7.25K | 6.35K | 146.21K |
| CommonStock | 18.07K | 7.25K | 6.35K | 146.21K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 53.41M | 42.55M | 12.18M | 10.57M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 8.50M | 6.74M | 6.40M | 6.04M |
| NonCurrentDeferredLiabilities | 7.77M | 6.71M | 6.14M | 5.56M |
| NonCurrentDeferredTaxesLiabilities | 7.77M | 6.71M | 6.14M | 5.56M |
| LongTermDebtAndCapitalLeaseObligation | 724.92K | 21.32K | 262.87K | 481.25K |
| LongTermCapitalLeaseObligation | 724.92K | 21.32K | 262.87K | 481.25K |
| CurrentLiabilities | 44.91M | 35.81M | 5.78M | 4.53M |
| CurrentDebtAndCapitalLeaseObligation | 1.09M | 241.55K | 218.38K | 196.99K |
| CurrentCapitalLeaseObligation | 88.35K | 241.55K | 218.38K | 196.99K |
| CurrentDebt | 1.00M | |||
| CurrentNotesPayable | 1.00M | 0.00 | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.29M | 2.23M | 2.16M | 1.76M |
| PayablesAndAccruedExpenses | 40.53M | 33.34M | 3.40M | 2.57M |
| CurrentAccruedExpenses | 4.19M | 17.03K | 476.30K | 1.41M |
| InterestPayable | 0.00 | |||
| Payables | 36.34M | 33.33M | 2.93M | 1.17M |
| OtherPayable | 22.65M | 28.40M | ||
| AccountsPayable | 13.69M | 4.93M | 2.93M | 1.17M |
| TotalAssets | 130.94M | 116.65M | 103.61M | 114.00M |
| TotalNonCurrentAssets | 103.00M | 102.43M | 69.24M | 69.44M |
| NonCurrentPrepaidAssets | 38.06K | 38.06K | 38.06K | 38.06K |
| GoodwillAndOtherIntangibleAssets | 102.15M | 102.15M | 68.75M | 68.75M |
| OtherIntangibleAssets | 92.80M | 92.80M | 59.40M | 59.40M |
| Goodwill | 9.35M | 9.35M | 9.35M | 9.35M |
| NetPPE | 818.69K | 246.25K | 455.86K | 650.17K |
| GrossPPE | 818.69K | 246.25K | 455.86K | 650.17K |
| OtherProperties | 818.69K | 246.25K | 455.86K | 650.17K |
| CurrentAssets | 27.93M | 14.22M | 34.37M | 44.56M |
| PrepaidAssets | 1.40M | 2.70M | 7.89M | 2.85M |
| Inventory | 22.29M | 8.27M | 0.00 | |
| FinishedGoods | 10.58M | 6.13M | ||
| WorkInProcess | 11.71M | 2.13M | ||
| CashCashEquivalentsAndShortTermInvestments | 4.25M | 3.25M | 26.48M | 41.71M |
| CashAndCashEquivalents | 4.25M | 3.25M | 26.48M | 41.71M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -26.55M | -28.20M | -29.06M | -28.36M |
| RepaymentOfDebt | 0.00 | -172.97K | ||
| IssuanceOfDebt | 1.30M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 32.30M | 13.80M | 13.80M | 0.00 |
| CapitalExpenditure | -40.01M | |||
| InterestPaidSupplementalData | 187.39K | 0.00 | ||
| EndCashPosition | 4.25M | 3.25M | 26.48M | 41.71M |
| BeginningCashPosition | 3.25M | 26.48M | 41.71M | 70.07M |
| ChangesInCash | 1.00M | -23.23M | -15.23M | -28.36M |
| FinancingCashFlow | 33.30M | 9.97M | 13.83M | 0.00 |
| CashFlowFromContinuingFinancingActivities | 33.30M | 9.97M | 13.83M | 0.00 |
| NetOtherFinancingCharges | -300.00K | -3.83M | ||
| ProceedsFromStockOptionExercised | 0.00 | 31.27K | 0.00 | 31.21M |
| NetCommonStockIssuance | 32.30M | 13.80M | 13.80M | 0.00 |
| CommonStockIssuance | 32.30M | 13.80M | 13.80M | 0.00 |
| NetIssuancePaymentsOfDebt | 1.30M | 0.00 | 0.00 | -172.97K |
| NetShortTermDebtIssuance | 1.30M | 0.00 | ||
| ShortTermDebtIssuance | 1.30M | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | -172.97K | ||
| LongTermDebtPayments | 0.00 | -172.97K | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -5.75M | -5.00M | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | -5.75M | -5.00M | 0.00 | 0.00 |
| NetOtherInvestingChanges | -5.75M | -5.00M | ||
| NetIntangiblesPurchaseAndSale | 0.00 | -40.00M | ||
| PurchaseOfIntangibles | 0.00 | -40.00M | ||
| NetPPEPurchaseAndSale | 0.00 | -6.94K | ||
| PurchaseOfPPE | 0.00 | -6.94K | ||
| OperatingCashFlow | -26.55M | -28.20M | -29.06M | -28.36M |
| CashFlowFromContinuingOperatingActivities | -26.55M | -28.20M | -29.06M | -28.36M |
| ChangeInWorkingCapital | 1.05M | -1.69M | -4.01M | 239.56K |
| ChangeInOtherWorkingCapital | 1.06M | 72.03K | 394.73K | -143.75K |
| ChangeInOtherCurrentLiabilities | -236.29K | -218.38K | -196.99K | -177.24K |
| ChangeInPayablesAndAccruedExpense | 12.94M | 1.54M | 832.86K | 671.72K |
| ChangeInAccruedExpense | 4.17M | -459.27K | -929.09K | 783.43K |
| ChangeInInterestPayable | 0.00 | -88.00K | ||
| ChangeInPayable | 8.77M | 2.00M | 1.76M | -111.72K |
| ChangeInAccountPayable | 8.77M | 2.00M | 1.76M | -111.72K |
| ChangeInPrepaidAssets | -64.21K | -945.39K | -5.04M | -111.18K |
| ChangeInInventory | -12.65M | -2.13M | 0.00 | |
| OtherNonCashItems | 26.60K | 284.18K | 102.00K | 378.20K |
| StockBasedCompensation | 10.84M | 11.84M | 6.62M | 3.91M |
| DeferredTax | 1.06M | 576.00K | 576.00K | 576.00K |
| DeferredIncomeTax | 1.06M | 576.00K | 576.00K | 576.00K |
| DepreciationAmortizationDepletion | 214.25K | 209.61K | 194.32K | 179.68K |
| DepreciationAndAmortization | 214.25K | 209.61K | 194.32K | 179.68K |
| Depreciation | 214.25K | 209.61K | 194.32K | 179.68K |
| OperatingGainsLosses | -166.56K | |||
| NetIncomeFromContinuingOperations | -39.74M | -39.43M | -32.54M | -33.64M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CTXR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|